Logo image of CNSP

CNS PHARMACEUTICALS INC (CNSP) Stock Fundamental Analysis

NASDAQ:CNSP - Nasdaq - US18978H4092 - Common Stock - Currency: USD

1.13  +0.07 (+6.6%)

After market: 1.12 -0.01 (-0.88%)

Fundamental Rating

2

Taking everything into account, CNSP scores 2 out of 10 in our fundamental rating. CNSP was compared to 198 industry peers in the Pharmaceuticals industry. While CNSP seems to be doing ok healthwise, there are quite some concerns on its profitability. CNSP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CNSP had negative earnings in the past year.
CNSP had a negative operating cash flow in the past year.
In the past 5 years CNSP always reported negative net income.
CNSP had a negative operating cash flow in each of the past 5 years.
CNSP Yearly Net Income VS EBIT VS OCF VS FCFCNSP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

CNSP's Return On Assets of -170.76% is on the low side compared to the rest of the industry. CNSP is outperformed by 85.35% of its industry peers.
CNSP's Return On Equity of -240.55% is on the low side compared to the rest of the industry. CNSP is outperformed by 71.72% of its industry peers.
Industry RankSector Rank
ROA -170.76%
ROE -240.55%
ROIC N/A
ROA(3y)-465.36%
ROA(5y)-324.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNSP Yearly ROA, ROE, ROICCNSP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CNSP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNSP Yearly Profit, Operating, Gross MarginsCNSP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

CNSP has more shares outstanding than it did 1 year ago.
CNSP has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CNSP has an improved debt to assets ratio.
CNSP Yearly Shares OutstandingCNSP Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
CNSP Yearly Total Debt VS Total AssetsCNSP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

CNSP has an Altman-Z score of -17.60. This is a bad value and indicates that CNSP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CNSP (-17.60) is worse than 80.81% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that CNSP is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.05, CNSP is in line with its industry, outperforming 56.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -17.6
ROIC/WACCN/A
WACCN/A
CNSP Yearly LT Debt VS Equity VS FCFCNSP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 3.43 indicates that CNSP has no problem at all paying its short term obligations.
CNSP has a better Current ratio (3.43) than 60.10% of its industry peers.
A Quick Ratio of 3.43 indicates that CNSP has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.43, CNSP is doing good in the industry, outperforming 61.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.43
Quick Ratio 3.43
CNSP Yearly Current Assets VS Current LiabilitesCNSP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

CNSP shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.26%.
EPS 1Y (TTM)5.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.85% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.72%
EPS Next 2Y40.89%
EPS Next 3Y24.95%
EPS Next 5Y14.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNSP Yearly Revenue VS EstimatesCNSP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 50M 100M 150M 200M
CNSP Yearly EPS VS EstimatesCNSP Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10K -20K -30K -40K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNSP. In the last year negative earnings were reported.
Also next year CNSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNSP Price Earnings VS Forward Price EarningsCNSP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNSP Per share dataCNSP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -200 -400 -600 -800

4.3 Compensation for Growth

CNSP's earnings are expected to grow with 24.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.89%
EPS Next 3Y24.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNSP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CNS PHARMACEUTICALS INC

NASDAQ:CNSP (5/2/2025, 8:00:01 PM)

After market: 1.12 -0.01 (-0.88%)

1.13

+0.07 (+6.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-13 2025-05-13
Inst Owners4.34%
Inst Owner Change-8.97%
Ins Owners0.03%
Ins Owner Change0%
Market Cap3.32M
Analysts80
Price Target204 (17953.1%)
Short Float %11.05%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-69.49%
Min EPS beat(2)-145.1%
Max EPS beat(2)6.12%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8788.89%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-116.05%
EPS NY rev (3m)-10702.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.54
EV/EBITDA N/A
EPS(TTM)-810
EYN/A
EPS(NY)-12.24
Fwd EYN/A
FCF(TTM)-5.82
FCFYN/A
OCF(TTM)-5.82
OCFYN/A
SpS0
BVpS2.1
TBVpS2.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -170.76%
ROE -240.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-465.36%
ROA(5y)-324.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 127.27%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.43
Quick Ratio 3.43
Altman-Z -17.6
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)74.13%
Cap/Depr(5y)104.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.27%
EPS Next Y98.72%
EPS Next 2Y40.89%
EPS Next 3Y24.95%
EPS Next 5Y14.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.03%
OCF growth 3YN/A
OCF growth 5YN/A